Applied Therapeutics, Inc.APLTEarnings & Financial Report
Relief Therapeutics is a Swiss biopharmaceutical company based in Geneva. The company focuses on developing drugs for serious diseases with few or no existing treatment options. Its lead compound, RLF-100, is a synthetic form of a natural peptide that protects the lung. The company was incorporated as Relief Therapeutics Holdings AG (RFLB.S) and listed on the SIX Swiss Exchange in 2016.
APLT Q3 FY2025 Key Financial Metrics
Revenue
$1.0M
Gross Profit
N/A
Operating Profit
$-16.8M
Net Profit
$-19.0M
Gross Margin
N/A
Operating Margin
-1675.8%
Net Margin
-1899.0%
YoY Growth
719.7%
EPS
$-0.13
Applied Therapeutics, Inc. Q3 FY2025 Financial Summary
Applied Therapeutics, Inc. reported revenue of $1.0M (up 719.7% YoY) for Q3 FY2025, with a net profit of $-19.0M (up 72.3% YoY) (-1899.0% margin).
Key Financial Metrics
| Total Revenue | $1.0M |
|---|---|
| Net Profit | $-19.0M |
| Gross Margin | N/A |
| Operating Margin | -1675.8% |
| Report Period | Q3 FY2025 |
Applied Therapeutics, Inc. Quarterly Revenue & Net Profit History
Applied Therapeutics, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q3 FY2025 | $1.0M | +719.7% | $-19.0M | -1899.0% |
| Q2 FY2025 | $0 | — | $-21.3M | N/A |
| Q1 FY2025 | $0 | — | $-21.8M | N/A |
| Q4 FY2024 | $-1.0K | +99.9% | $44.0M | -4400700.0% |
| Q2 FY2024 | $144.0K | — | $2.9M | 2012.5% |
| Q1 FY2024 | $190.0K | -98.2% | $-83.9M | -44177.9% |
| Q4 FY2023 | $-667.0K | — | $-37.7M | 5649.0% |
| Q3 FY2023 | $0 | — | $-42.4M | N/A |
Income Statement
| Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $-667000 | $190000 | $144000 | $-1000 | $0 | $0 | $1.0M |
| YoY Growth | N/A | N/A | -98.2% | N/A | 99.9% | N/A | N/A | 719.7% |
Balance Sheet
| Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $45.2M | $54.8M | $151.2M | $127.8M | $86.7M | $56.9M | $37.3M | $34.4M |
| Liabilities | $56.2M | $72.0M | $83.9M | $55.4M | $29.7M | $20.2M | $19.9M | $34.9M |
| Equity | $-11.0M | $-17.1M | $67.3M | $72.4M | $57.0M | $36.7M | $17.4M | $-561000 |
Cash Flow
| Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-14.7M | $-17.0M | $-18.9M | $-22.6M | $-19.5M | $-28.6M | $-20.3M | $-18.4M |